Novel mutations and polymorphisms in the Fanconi anemia group C gene

Rachel A. Gibson(Guy's Hospital), Neil V. Morgan(Guy's Hospital), Laura H. Goldstein(Guy's Hospital), I. C. Pearson(Guy's Hospital), Ian Kesterton(Guy's Hospital), Nicola Foot(Guy's Hospital), S Jansen(University of the Free State), Charmaine Havenga(University of the Free State), Thomas C. Pearson(University of the Free State), Thomy de Ravel(University of the Witwatersrand), Richard J. Cohn(University of the Witwatersrand), Isabel Marques(South African Institute for Medical Research), Inderjeet Dokal(Hammersmith Hospital), Irene Roberts(Hammersmith Hospital), Judith Marsh(St George's Hospital), Sarah E. Ball(St George's Hospital), R D Milner(King Faisal Specialist Hospital & Research Centre), Juan Clinton Llerena(Brazilian Institute of Geography and Statistics), Elena Samochatova(Ministry of Health of the Russian Federation), Sheila Mohan(Institute of Child Health), Pushpa Vasudevan(Institute of Child Health), Farkondeh Birjandi(Guy's Hospital), Atieh Hajianpour(Boston Children's Hospital), M. Murer‐Orlando(Guy's Hospital), Christopher G. Mathew(Guy's Hospital)
Cited by 45

Abstract

Fanconi anemia (FA) is an autosomal recessive disorder associated with hypersensitivity to DNA cross-linking agents and bone marrow failure. At least four complementation groups have been defined, and the FA group C gene (FAC) has been cloned. We have screened 76 unrelated FA patients of diverse ethnic and geographic origins and from unknown complementation groups for mutations in the FAC gene either by chemical cleavage mismatch analysis or by single-strand conformational polymorphism (SSCP). Five mutations were detected in four patients (5.3%), including two novel mutations (W22X and L496R). Nine polymorphisms were detected, seven of which have not been described previously (663A-->G, L190F, IVS6 + 30C-->T, I312V, V449M, Q465R, and 1974G-->A). Six of the nine polymorphisms occurred in patients or controls from the Tswana or Sotho chiefdoms of South Africa and were not found in 50 unrelated European controls. Restriction site assays were established for all 8 pathogenic mutations identified in the FAC gene to date and used to screen a total of 94 unrelated FA patients. This identified only one other group C patient, who was homozygons for the mutation IVS4 + 4A-->T. This study indicates that the proportion of FA patients from complementation group C is generally likely to be less than 10%. Guidelines for the selection of FA patients for FAC mutation screening are proposed.


Related Papers

No related papers found

Powered by citation graph analysis